{"doi":"10.1136/jitc-2024-009867","title":"Novel and potent MICA/B antibody is therapeutically effective in <i>KRAS LKB1</i> mutant lung cancer models","abstract":"BACKGROUND: (STK11, KL) mutant non-small cell lung cancers (NSCLC) do not respond well to current immune checkpoint blockade therapies, however targeting major histocompatibility complex class I-related chain A or B (MICA/B), could pose an alternative therapeutic strategy through activation of natural killer (NK) cells. METHODS: Expression of NK cell activating ligands in NSCLC cell line and patient data were analyzed. Cell surface expression of MICA/B in NSCLC cell lines was determined through flow cytometry while ligand shedding in both patient blood and cell lines was determined through ELISA. We engineered an antibody-dependent cellular cytotoxicity (ADCC) enhanced MICA/B monoclonal antibody, AHA-1031, which prevents ligand shedding without interfering with binding to natural killer group 2D while targeting cancer cells via superior ADCC. We performed in vitro assays using ELISA and flow cytometry-based assays to confirm that our antibody potently binds to and stabilizes MICA/B expression across lung cancer and other solid tumor cell lines. Additionally, we used two KL mutant NSCLC cell lines and a KL mutant patient-derived xenograft (PDX) model to demonstrate in vivo antitumor efficacy and flow cytometry analysis for immune cell activation profiling. RESULTS: NSCLC cell lines exhibit high MICA/B expression and secrete soluble MICA/B in vitro. Soluble MICA/B is also detected in patient blood samples. AHA-1031 binds to the α3 domain of MICA/B, preventing shedding and targeting tumor cells to ADCC. AHA-1031 exhibits high affinity and specificity to MICA/B, preventing MICA/B shedding in tumor lines and inducing ADCC in vitro. Our antibody also effectively binds and stabilizes MICA/B expression in additional tumor types and demonstrates broad specificity. We show that in two KL mutant NSCLC xenograft models and a KL mutant PDX model, treatment with AHA-1031 monotherapy significantly inhibits tumor growth compared with vehicle-treated animals with no observable toxicity. Tumor tissues from treated mice exhibit significantly increased immune cell infiltrates and activated NK cell populations. CONCLUSIONS: Activating NK cells through MICA/B stabilization and inducing ADCC offers an alternative and potent therapy option in KL tumors. MICA/B are shed across different tumors making this therapeutic strategy universally applicable.","journal":"Journal for ImmunoTherapy of Cancer","year":2025,"id":516300,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":9,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9625,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2025-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1002877,"name":"Manoj K. Sabnani","orcid":"0000-0002-3723-0315","position":1,"is_corresponding":false},{"id":687802,"name":"Laura Gray","orcid":"0000-0002-5958-4405","position":2,"is_corresponding":false},{"id":612806,"name":"Qing Deng","orcid":"0000-0001-9835-6889","position":3,"is_corresponding":false},{"id":1382124,"name":"Nusrat U A Saleh","orcid":null,"position":4,"is_corresponding":false},{"id":253870,"name":"Luc Girard","orcid":"0000-0002-6688-5281","position":5,"is_corresponding":false},{"id":643154,"name":"Yujiro Naito","orcid":"0000-0003-0633-4936","position":6,"is_corresponding":false},{"id":1382125,"name":"Kentaro Masahiro","orcid":null,"position":7,"is_corresponding":false},{"id":71347,"name":"John D. Minna","orcid":"0000-0002-7776-0767","position":8,"is_corresponding":false},{"id":1553,"name":"David E. Gerber","orcid":"0000-0002-7812-6741","position":9,"is_corresponding":false},{"id":428513,"name":"Shohei Koyama","orcid":"0000-0002-6897-9417","position":10,"is_corresponding":false},{"id":1382126,"name":"Zhiqian Lucy Liu","orcid":null,"position":11,"is_corresponding":false},{"id":1381650,"name":"Hemanta Baruah","orcid":"0009-0003-4932-4882","position":12,"is_corresponding":false},{"id":268281,"name":"Esra A. Akbay","orcid":"0000-0002-4149-2529","position":13,"is_corresponding":false},{"id":1382123,"name":"Ryan Kowash","orcid":null,"position":0,"is_corresponding":true}],"reference_count":40,"raw_metadata":null,"created_at":"2026-07-19T02:48:49.486328Z","pmid":"39762078","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}